LYEL (STOCKS)
Lyell Immunopharma, Inc. Common Stock
$24.800000
+2.410000 (+10.76%)
Prev close: $22.390000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Lynn Seely
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $580.58M
- Employees
- 300
- P/E (TTM)
- -1.63
- P/B (TTM)
- 1.92
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
6
Buy
1
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-7.50 | $-2.28 | -5.2240 | -229.53% |
|
Sep 2025 (Q3)
|
$-2.13 | $-2.70 | +0.5654 | +20.98% |
|
Jun 2025 (Q2)
|
$-2.89 | $-3.66 | +0.7650 | +20.93% |
|
Mar 2025 (Q1)
|
$-3.54 | $-3.67 | +0.1320 | +3.59% |
Financial Statements
| Revenues | $36.00K |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $269.44M |
| Nonoperating Income/Loss | -$5.04M |
| Operating Expenses | $269.44M |
| Operating Income/Loss | -$269.40M |
| Income/Loss From Continuing Operations After Tax | -$274.45M |
| Income/Loss From Continuing Operations Before Tax | $36.00K |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$274.45M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$274.45M |
| Net Income/Loss Available To Common Stockholders, Basic | -$274.45M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$16.06 |
| Diluted Earnings Per Share | -$16.06 |
| Basic Average Shares | 17,093,000 |
| Diluted Average Shares | 17,093,000 |
| Assets | $340.05M |
| Current Assets | $260.94M |
| Noncurrent Assets | $79.11M |
| Fixed Assets | $34.77M |
| Other Non-current Assets | $44.34M |
| Liabilities | $91.85M |
| Current Liabilities | $49.41M |
| Accounts Payable | $2.89M |
| Other Current Liabilities | $46.52M |
| Noncurrent Liabilities | $42.44M |
| Equity | $248.20M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $248.20M |
| Liabilities And Equity | $340.05M |
| Net Cash Flow From Operating Activities | -$150.02M |
| Net Cash Flow From Operating Activities, Continuing | -$150.02M |
| Net Cash Flow From Investing Activities | $54.10M |
| Net Cash Flow From Investing Activities, Continuing | $54.10M |
| Net Cash Flow From Financing Activities | $50.41M |
| Net Cash Flow From Financing Activities, Continuing | $50.41M |
| Net Cash Flow | -$45.52M |
| Net Cash Flow, Continuing | -$45.52M |
| Comprehensive Income/Loss | -$274.50M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$274.50M |
| Other Comprehensive Income/Loss | -$49.00K |